Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

lity of single infusions of an escalating dose of an autologous (a patient's own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). Nine HIV-infected subjects (three cohorts of three subjects each) classified as immune non-responders (INR) with sub-optimal T-cell levels and no detectable viral load on long-term ART were enrolled into the trial.  Subjects received SB-728-T at doses of approximately 5, 20 or 30 billion cells and remained on their existing antiviral therapy throughout the study without undergoing a TI.
Cohort 5
Ten HIV-infected subjects heterozygous for the CCR5 delta-32 mutation (i.e. with one CCR5 gene that is naturally modified) who are currently on ART have been enrolled and have received a single intravenous infusion of SB-728-T (12.6 to 23.5 billion cells). Two months after SB-728-T treatment, subjects underwent a 16 week TI during which time their ART was discontinued. ART was reinstituted in subjects whose CD4 T-cell counts dropped to <350 cells/ mm3 and/or whose HIV-RNA increased to >100,000 /mL for three consecutive weekly measurements. At the end of the TI, subjects with a sustained detectable HIV viral load were reinstituted on ART. Subjects with an undetectable viral load can remain off ART until HIV RNA levels are >10,000 copies/mL for three consecutive weekly measurements or their CD4 T-cell count drops below 500 cell/mm3 for two consecutive weekly measurements.

About SB-728-1101
SB-728-1101 is an open-label, dose escalation, multi-center study designed primarily to evaluate the safety and tolerability of escalating doses of cyclophosphamide (Cytoxan) administered prior to SB-728-T infusion. Cytoxan is a drug that is used to transiently reduce the numbers of T-cells in the body, which then rapidly repopulate once the drug is discontinued, and it is into this "growth" environment that SB-728-T is infused. Such lymphodepletive treatment has bee
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... for solid tumor cancers, announced today that its DCVax-L ... a "Promising Innovative Medicine" (PIM) under the new "Early ... in April 2014.  A PIM is the first step ... the EAMS.  The PIM designation for ...
(Date:9/16/2014)... OKLAHOMA CITY , Sept. 16, 2014 ... biopharmaceutical company developing novel orally active drugs ... existing antibiotics, announced today a $1.4 million ... investing arm of life sciences accelerator Accele ... from i2E, Inc., a nationally recognized private ...
(Date:9/16/2014)... CALGARY, Alberta , Sept. 16, 2014 /PRNewswire/ ... $1.4 billion industry in less than two years, ... along the way. A huge opportunity exists for ... Today, Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind ... providers based on years of clinical research linking ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... DIEGO, June 10, 2011 Volcano Corporation (NASDAQ: ... precision intravascular diagnosis and therapy guidance tools designed to ... said today that it will be participating in the ... on Thursday, June 16. The presentation by ...
... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: ... 98 percent of votes cast and 79 percent of shares ... anticipate the closing of the transaction will occur within one ...
Cached Medicine Technology:TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 2TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 3TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 4
(Date:9/16/2014)... 16, 2014 Cloud based mobile ... (HLS) & UStream API’S to serve m3u8 streams on ... for broadcasting live video events with hundreds of thousands ... The App Builder is known for making beautiful and ... BlackBerry and Windows 8 and already over 100,000 apps ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
(Date:9/16/2014)... other workplace incident, a statistic that transport safety experts ... hosted by QUT,s Centre for Accident Research & Road ... Transport Conference (OSIT) to be held on the Gold ... from all facets of transport safety including roads, rail, ... , CARRS-Q research fellow Darren Wishart said the aim ...
(Date:9/16/2014)... Definitive Healthcare , the leading ... is pleased to announce the release of its ... available for subscription, features detailed hospital profiles that ... , The Canadian database spans Canada’s ten providences ... 750 hospitals. Each hospital profile provides data ...
(Date:9/16/2014)... The Muscular Dystrophy Association is offering assistance ... affected by muscle disease, including muscular dystrophy, amyotrophic ... MDA offers this service annually for adults and ... compromised respiratory function — including difficulty coughing or ... increased risk of serious and possibly life-threatening complications ...
Breaking Medicine News(10 mins):Health News:A heart-felt need for dairy food 2Health News:CARRS-Q Host International Transport Safety Conference 2Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:MDA Offers Flu Shots to Those Affected by Muscle Disease 2
... , , BETHESDA, ... innovative voice data solutions, today announced the availability of ... NotifierRx will help hospitals improve standards of care and ... interactive voice-controlled services. , , NotifierRx ...
... , , , ... Kaiser Permanente has launched its sixth season of the Thrive advertising ... health care organization,s commitment to the total health of its members ... new ads -- "Emerald Cities" and "Connected" -- illustrate Kaiser Permanente,s ...
... , , , ... NTRI ), a leading provider of weight management programs ... offer consumers striving for a late-summer shape up, some easy, top-of-mind tips ... , , According to Sansone, there ...
... Industry Veteran to Lead PI Pharmaceutical Business Unit ... Physicians Interactive LLC (PI), a leader in digital sales and marketing ... Pingle has been named President of PI. Pingle will report to ... lead the company,s pharmaceutical business unit. , , ...
... be wary when walking around parking lots, crossing streets ... disturbing research to kick off the school year: A ... near schools is distracted. , A whole variety of ... eating, smoking and even reading -- are keeping drivers ...
... , , PITTSBURGH, Sept. 1 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP ... launched the product, will market this product with 180 days ... is indicated for the treatment or prevention of bronchospasm in ...
Cached Medicine News:Health News:Audiopoint Adds Voice to Healthcare Reform Debate 2Health News:Audiopoint Adds Voice to Healthcare Reform Debate 3Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 2Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 4Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 5Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 6Health News:Physicians Interactive Names Sanjay Pingle President 2Health News:Physicians Interactive Names Sanjay Pingle President 3Health News:Drivers Distracted When Near Schools 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: